BioSpace News Archive

Merrimack Pharmaceuticals, Inc. announced that the stockholders at a Special Meeting held overwhelmingly approved adopting a Plan of Dissolution.

Bristol Myers Squibb announced the Phase 3 CheckMate -73L trial did not meet its primary endpoint of progression-free survival in unresectable, locally advanced stage III non-small cell lung cancer.

Tevogen Bio Holdings Inc. has entered into a binding term sheet [with an existing investor] to secure up to $50 million of financing.

Inhibrx, Inc. announced that in connection with the previously announced distribution by the Company of 92% of shares of common stock of its subsidiary Inhibrx Biosciences, Inc. to holders of shares of the Company’s common stock on a pro rata basis.

On May 10, 2024, the impactful international academic journal, Science Immunology, a sub-journal of Science, published a research paper titled “Single-cell analysis of anti-BCMA CAR T cell therapy in patients with central nervous system autoimmunity”.

Entera Bio Ltd., a leader in the development of orally delivered peptides and small therapeutic proteins, reported financial results and key business updates for the quarter ended March 31, 2024.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Gossamer Bio, Inc. announced that the Compensation Committee of Gossamer’s Board of Directors approved the grant, effective May 8, 2024, to three new non-executive employees of non-qualified stock option awards to purchase up to an aggregate of 323,000 shares of the Company’s common stock under the Gossamer Bio, Inc. 2023 Employment Inducement Incentive Award Plan.

Revelation Biosciences, Inc., a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, reported its three months ended March 31, 2024 financial results.

Evolus, Inc., a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, reported the grant of non-qualified stock options to purchase an aggregate of 10,990 shares of Evolus and an aggregate of 42,759 restricted stock units of the company’s common stock to 14 newly hired non-executive employees of the company.